Risk-adjusted NPV for pre-revenue biotech pipelines: how the math actually works

from Leaders Insights — Finance · host Leaders Insights

Most valuation frameworks break down when applied to a drug candidate that has never generated a dollar of revenue and may never reach patients. Risk-adjusted NPV fixes that problem, but only if you understand what the model is actually doing and where it quietly fails.

Episode metadata supplied by the publisher feed · Published Sep 11, 2026

Embed this episode

Attribution link and audio player

Ready to play

Risk-adjusted NPV for pre-revenue biotech pipelines: how the math actually works

0:00 5:02

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Leaders Insights — Finance?

This episode is 5 minutes long.

When was this Leaders Insights — Finance episode published?

This episode was published on September 11, 2026.

Can I download this Leaders Insights — Finance episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!